Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis
Cells · 2024
DOI: 10.3390/cells13040295 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Chandra Sekhar Yadavalli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorder Center, School of Medicine, Tulane University, New Orleans, LA 70…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Enteritis, Eosinophilia, Gastritis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, NIH.
Abstract (Originalsprache)
Background and Aims: Ultrasonography has shown that eosinophils accumulate in each segment of the esophageal mucosa in human EoE, ultimately promoting esophageal motility dysfunction; however, no mechanistic evidence explains how or why this accumulation occurs.
Methods
Quantitative PCR, ELISA, flow cytometry, immunostaining, and immunofluorescence analyses were performed using antibodies specific to the related antigens and receptors.
Results
In deep esophageal biopsies of EoE patients, eosinophils and mast cells accumulate adjacent to nerve cell-derived VIP in each esophageal segment. qRT-PCR analysis revealed five- to sixfold increases in expression levels of VIP, CRTH2, and VAPC2 receptors and proteins in human blood- and tissue-accumulated eosinophils and mast cells. We also observed a significant correlation between mRNA CRTH2 levels and eosinophil- and nerve cell-derived VIPs in human EoE (p < 0.05). We provide evidence that eosinophil and mast cell deficiency following CRTH2 antagonist treatment improves motility dysfunction in a chronic DOX-inducible CC10-IL-13 murine model of experimental EoE.
Conclusions
CRTH2 antagonist treatment is a novel therapeutic strategy for inflammatory cell-induced esophageal motility dysfunction in IL-13-induced chronic experimental EoE.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorder Center, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
- Division of Gastroenterology, Cincinnati Childrens Medical Center, Cincinnati, OH 45229, USA.
- Division of Gastroenterology, School of Medicine, Tulane University, New Orleans, LA 70118, USA.
- Division of Gastroenterology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
- Division of Physiology, Cincinnati University, Cincinnati, OH 45220, USA.
ORCID-Profile: Chandra Sekhar Yadavalli, Chandrasekhar Kathera
Förderung
- NIAID NIH HHS
- NIH HHS
- NIH
Zitieren
APA
Yadavalli, C. S., Upparahalli Venkateshaiah, S., Verma, A. K., Kathera, C., Duncan, P. S., Vaezi, M., Paul, R. J., & Mishra, A. (2024). Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis. Cells. https://doi.org/10.3390/cells13040295
Vancouver
Yadavalli CS, Upparahalli Venkateshaiah S, Verma AK, Kathera C, Duncan PS, Vaezi M, et al. Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis. Cells. 2024. doi:10.3390/cells13040295
BibTeX
@article{Yadavalli2024,
author = {Yadavalli, Chandra Sekhar and Upparahalli Venkateshaiah, Sathisha and Verma, Alok K and Kathera, Chandrasekhar and Duncan, Pearce S and Vaezi, Michael and Paul, Richard J and Mishra, Anil},
title = {Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13040295}
}
EUVIMED